The Exciting New Field of HER2-Low Breast Cancer Treatment.
Auteurs : Eiger D, Agostinetto E, Saude Conde R, de Azambuja E
Année : 2021
Journal : Cancers (Basel)
Volume : 13
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Auteurs : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Année : 2021
Journal : Breast
Volume : 57
Pages : 86-94
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
Auteurs : Agostinetto E, Vian L, Caparica R, Bruzzone M, Ceppi M, Lambertini M, Pondé N, de Azambuja E
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100091
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Auteurs : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Année : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Auteurs : Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E
Année : 2021
Journal : Eur J Clin Invest
Pages : e13535
Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Auteurs : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Année : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116
159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)
Auteurs : Eiger D, de Azambuja E, Moreau M, Bondele J, Sotiriou C, Franzoi MA, Brandão M, Rediti M, Wang X, Awada A, Kotecki N
Année : 2020
Journal : Ann Oncol
Volume : 31(2)
Pages : S73-S74
Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy.
Auteurs : Caparica R, Amorim L, Amaral P, Uratani L, Muniz D, Hendlisz A, de Azambuja E, Glasberg J, Takahashi TK, Filho EA, Canellas R, Saragiotto D, Sabbaga J, Mak M
Année : 2020
Journal : BMJ Support Palliat Care
Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
Auteurs : Franzoi MA, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5
CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
Auteurs : Agostinetto E, Caparica R, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Auteurs : Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Année : 2020
Journal : ESMO Open
Volume : 5
Clinical management of first-line advanced triple-negative breast cancer patients
Auteurs : Rediti M, Punie K, de Azambuja E, Naert E, Taylor D, Duhoux FP, Denys H, Awada A, Wildiers H, Ignatiadis M
Année : 2020
Journal : Belgian J Medical Oncology
Volume : 14(7)
Pages : 333-338
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Auteurs : Di Cosimo S, Porcu L, Agbor-Tarh D, Cinieri S, Franzoi MA, De Santis MC, Saura C, Huober J, Fumagalli D, Izquierdo M, Piccart-Gebhart M, Daidone MG, de Azambuja E
Année : 2020
Journal : Breast Cancer Res
Volume : 22
Pages : 115
Are We RESPECTing Older Patients With Breast Cancer?
Auteurs : de Azambuja E, Pondé N, Gelber Rd
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 3727-3730
Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.
Auteurs : de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, Collignon J, Lybaert W, Verheezen J, Rutten A, Vuylsteke P, Goeminne JC, Demey W, Van Beckhoven D, Deblonde J, Rottey S, Geukens T, Punie K
Année : 2020
Journal : ESMO Open
Volume : 5
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies.
Auteurs : Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, Curigliano G, de Azambuja E
Année : 2020
Journal : Eur J Cancer
Volume : 139
Pages : 43-50
De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?
Auteurs : Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Année : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 108
Pages : 1040-1046
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Auteurs : Brandão M, Maurer C, Ziegelmann PK, Pondé NF, Ferreira A, Martel S, Piccart-Gebhart M, de Azambuja E, Debiasi M, Lambertini M
Année : 2020
Journal : ESMO Open
Volume : 5
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.
Auteurs : de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, Romano M, Capelan M, Prasad R, Pattu P, Massard C, Portera C, Saini ML, Singh BP, Venkitaraman R, McNally R, Leone M, Grande E, Gupta S
Année : 2020
Journal : Oncol Ther
Volume : 8
Pages : 171-182
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
Auteurs : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 2883-2891